We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+18.42%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.07B
AUM Growth
+$166M
Cap. Flow
+$47.2M
Cap. Flow %
4.41%
Top 10 Hldgs %
29.4%
Holding
105
New
13
Increased
43
Reduced
32
Closed
11

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$17.2M
2
DOCS icon
Doximity
DOCS
+$13.3M
3
AMGN icon
Amgen
AMGN
+$11.4M
4
NUVL
Nuvalent
NUVL
+$10.9M
5
VERA icon
Vera Therapeutics
VERA
+$10.3M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$19M
2
CAH icon
Cardinal Health
CAH
+$14.8M
3
ABT icon
Abbott
ABT
+$13.2M
4
CYTK icon
Cytokinetics
CYTK
+$13.1M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
76
Ocular Therapeutix
OCUL
$2.06B
$3.22M 0.3%
265,000
+63,000
+31% +$765K
ASND icon
77
Ascendis Pharma A/S
ASND
$16.6B
$3.2M 0.3%
+15,000
New +$3.1M
JANX icon
78
Janux Therapeutics
JANX
$1.01B
$3.11M 0.29%
225,377
+125,250
+125% +$2.95M
PRVA icon
79
Privia Health
PRVA
$2.81B
$2.96M 0.28%
125,000
-69,189
-36% -$1.68M
STVN icon
80
Stevanato
STVN
$5.66B
$2.96M 0.28%
147,025
+96,025
+188% +$2.23M
VKTX icon
81
Viking Therapeutics
VKTX
$3.97B
$2.92M 0.27%
83,000
-133,288
-62% -$4.72M
CYTK icon
82
Cytokinetics
CYTK
$10.7B
$2.82M 0.26%
44,375
-210,875
-83% -$13.1M
A icon
83
Agilent Technologies
A
$42.2B
$2.72M 0.25%
+20,000
New +$2.87M
XNCR icon
84
Xencor
XNCR
$1.63B
$2.54M 0.24%
165,750
– –
CNTA
85
DELISTED
Centessa Pharmaceuticals
CNTA
$2.5M 0.23%
+100,000
New +$2.53M
TGTX icon
86
TG Therapeutics
TGTX
$7.66B
$2.18M 0.2%
73,250
-19,750
-21% -$645K
BNTX icon
87
BioNTech
BNTX
$23.2B
$1.99M 0.19%
20,870
-15,000
-42% -$1.51M
WST icon
88
West Pharmaceutical
WST
$24.6B
$1.93M 0.18%
+7,000
New +$1.91M
CNC icon
89
Centene
CNC
$32.7B
$1.9M 0.18%
46,231
-123,769
-73% -$4.63M
QURE icon
90
uniQure
QURE
$3.12B
$1.9M 0.18%
+79,375
New +$3.06M
DNLI icon
91
Denali Therapeutics
DNLI
$4B
$1.65M 0.15%
100,000
– –
STE icon
92
Steris
STE
$23.4B
$1.52M 0.14%
+6,000
New +$1.51M
IRTC icon
93
iRhythm Holdings
IRTC
$4.02B
$1.24M 0.12%
7,000
– –
ATEC icon
94
Alphatec Holdings
ATEC
$1.46B
$421K 0.04%
20,000
+2,000
+11% +$37K
ABT icon
95
Abbott
ABT
$190B
– –
-98,500
Closed -$13.2M
AKRO
96
DELISTED
Akero Therapeutics
AKRO
– –
-230,600
Closed -$10.9M
ANNX icon
97
Annexon
ANNX
$868M
– –
-823,000
Closed -$2.51M
CAH icon
98
Cardinal Health
CAH
$56.1B
– –
-94,000
Closed -$14.8M
DVAX
99
DELISTED
Dynavax Technologies
DVAX
– –
-772,000
Closed -$7.67M
EXAS
100
DELISTED
Exact Sciences
EXAS
– –
-348,000
Closed -$19M
1 2 3
4
5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Rhenman & Partners Asset Management held 105 positions worth $1.07B, up 18% from $904M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $47.2M of net new capital in Q4 2025, opening 13 new positions and adding to 43 existing holdings. Its largest new stake was Amgen: 36,000 shares worth $11.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $13.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q4 2025 buy was Amgen: 36,000 shares worth $11.8M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q4 2025, an estimated $17.2M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2025 reduction was Cytokinetics, cutting an estimated $13.1M.
  • Rhenman & Partners Asset Management fully exited Exact Sciences in Q4 2025, selling an estimated $19M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.07B portfolio in Q4 2025.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 11 in Q4 2025.
  • Rhenman & Partners Asset Management's portfolio value rose 18% quarter-over-quarter to $1.07B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.